Skip to main content
Clinical Trials/NCT00875498
NCT00875498
Completed
Not Applicable

Intermittent Theta Burst Stimulation (iTBS) for the Treatment of Negative Symptoms in Schizophrenia

Hôpital le Vinatier1 site in 1 country22 target enrollmentNovember 2008
ConditionsSchizophrenia

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Schizophrenia
Sponsor
Hôpital le Vinatier
Enrollment
22
Locations
1
Primary Endpoint
Scale for the Assessment of Negative Symptoms (SANS)
Status
Completed
Last Updated
10 years ago

Overview

Brief Summary

The purpose of this study is to determine whether the iTBS is an effective treatment of the negative symptoms of schizophrenia.

Detailed Description

This study will evaluate whether the intermittent Theta Burst Stimulation (iTBS), a new high frequency TMS protocol is efficient in the treatment of the Negative Symptoms of schizophrenia. Neuroimaging studies demonstrate that hypoactivity in the left dorsolateral prefrontal cortex (LDLPFC) was associated with negative symptoms. The investigators hypothesize that iTBS applied to LDLPFC will improve negative symptoms and will improve activity of the LDLPFC measured with Magnetic Resonance Spectroscopy (MRS).

Registry
clinicaltrials.gov
Start Date
November 2008
End Date
July 2015
Last Updated
10 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Hôpital le Vinatier
Responsible Party
Principal Investigator
Principal Investigator

Dr. E. Poulet

PUPH

Hôpital le Vinatier

Eligibility Criteria

Inclusion Criteria

  • Schizophrenia according to DSM-IV
  • Negative symptoms for at least 6 weeks
  • Medication resistance according to Kane et al., 1988
  • Age between 18 and 50 years old
  • Informed consent

Exclusion Criteria

  • Contraindication to TMS
  • Pregnancy

Outcomes

Primary Outcomes

Scale for the Assessment of Negative Symptoms (SANS)

Time Frame: before, after 2 weeks of treatment, and 3 times follow-up (1, 3 and 6 months)

Secondary Outcomes

  • Neurochemical impact of treatment measured by 1H-MRS, DTI and resting MRI(3 times, before treatment, immediatly after treatment and a last evaluation 3 months after)

Study Sites (1)

Loading locations...

Similar Trials